Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(<i>R</i>), 6(<i>S</i>), 1’(<i>R</i>), 6’(<i>S</i>), 11(<i>R</i>), 17(<i>S</i>)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax

Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(<i>R</i>), 6(<i>S</i>), 1’(<i>R</i>), 6’(<i>S</i>), 11(<i>R</i>), 17(<i>S</i>)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax

Treatment of acute myeloid leukemia (AML) patients is still hindered by resistance and relapse, resulting in an overall poor survival rate. Recently, combining specific B-cell lymphoma (Bcl)-2 inhibitors with compounds downregulating myeloid cell leukemia (Mcl)-1 has been proposed as a new effective...

Full description

Bibliographic Details
Main Authors: Cristina Florean, Kyung Rok Kim, Michael Schnekenburger, Hyun-Jung Kim, Céline Moriou, Cécile Debitus, Mario Dicato, Ali Al-Mourabit, Byung Woo Han, Marc Diederich
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Marine Drugs
Subjects:
acute myeloid leukemia
ABT-199
Mcl-1
bromotyrosine
(+)-11(<i>R</i>), 17(<i>S</i>)-fistularin-3
configuration
anticancer drug combination
Online Access:https://www.mdpi.com/1660-3397/16/12/518

Internet

https://www.mdpi.com/1660-3397/16/12/518

Similar Items